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ABSTRACT
Background Ventilator-associated pneumonia (VAP) is
the most commonly fatal nosocomial infection. Clinical
diagnosis of VAP remains notoriously inaccurate. The
hypothesis was tested that significantly augmented
inflammatory markers distinguish VAP from conditions
closely mimicking VAP.
Methods A prospective, observational cohort study was
carried out in two university hospital intensive care units
recruiting 73 patients with clinically suspected VAP, and
a semi-urban primary care practice recruiting a reference
group of 21 age- and sex-matched volunteers. Growth of
pathogens at >104 colony-forming units (cfu)/ml of
bronchoalveolar lavage fluid (BALF) distinguished VAP
from “non-VAP”. Inflammatory mediators were quantified
in BALF and serum. Mediators showing significant
differences between patients with and without VAP were
analysed for diagnostic utility by receiver operator
characteristic (ROC) curves.
Results Seventy-two patients had recoverable
lavaged24% had VAP. BALF interleukin-1b (IL-1b), IL-8,
granulocyte colony-stimulating factor and macrophage
inflammatory protein-1a were significantly higher in the
VAP group (all p<0.005). Using a cut-off of 10 pg/ml,
BALF IL-1b generated negative likelihood ratios for VAP of
0.09. In patients with BALF IL-1b <10 pg/ml the post-
test probability of VAP was 2.8%. Using a cut-off value for
IL-8 of 2 ng/ml, the positive likelihood ratio was 5.03.
There was no difference in cytokine levels between
patients with sterile BALF and those with growth of
<104 cfu/ml.
Conclusions BALF IL-1b and IL-8 are amongst the
strongest markers yet identified for accurately
demarcating VAP within the larger population of patients
with suspected VAP. These findings have potential
implications for reduction in unnecessary antibiotic use
but require further validation in larger populations.
INTRODUCTION
Ventilator-associated pneumonia (VAP) occurs in
up to 20% of patients mechanically ventilated for
>48 h and is typically associated with mortality
rates of w30%.1 2 VAP therefore has a higher
mortality than any other hospital-acquired infec-
tion, and exerts a large ﬁnancial burden on health
services.3 Although estimates of the attributable
mortality vary, most studies describe a signiﬁcant
associated mortality and morbidity.1 3 4
The optimal methods and criteria required to
make a diagnosis of VAP remain contentious.1
However, it is generally accepted that only
approximately a quarter to one-third of patients
with clinically suspected VAP satisfy predeﬁned
microbiological criteria for pneumonia.5 6 The clin-
ical diagnosis of VAP is made relatively frequently in
the intensive care unit (ICU). This can result in
empirical antibiotic treatment, with the inherent
risk of overprescribing.7e9 Therefore, in recent years
attempts have been made to identify biological
markers that can distinguish VAP accurately, rapidly
and practically.10e12
Given the key roles played by inﬂammatory
cytokines and neutrophils in the natural history of
pneumonia, it is plausible that discriminatory
markers of infection may be found in the innate
immune system. We hypothesised that in critically
ill patients pneumonia would drive a further
increase in pulmonary inﬂammation, with inﬂam-
matory mediators distinguishing VAP from condi-
tions that mimic VAP.
MATERIALS AND METHODS
Patients
This prospective, observational, cohort study was
performed in two university hospital general ICUs
admitting all patients except those undergoing
cardiothoracic surgery. Patients were screened daily
for possible VAP, and were assessed for enrolment
as soon as the clinical suspicion was raised. Where
enrolment occurred, bronchoscopy took place
within 6 h of clinical diagnosis. Demographic
details, co-morbidities and prescribed medications
were recorded. The severity of presenting illness was
assessed by an Acute Physiology and Chronic
Health Evaluation II (APACHE II) score calculated
within 24 h of ICU admission. Patients were eligible
if they fulﬁlled recognised criteria for clinically
suspected VAPdthat is, mechanical ventilation for
at least 48 h, new and persisting inﬁltrates on
a chest radiograph and at least two of the following:
purulent tracheal secretions, temperature >388C or
white cell count >113109/ldbased on a modiﬁca-
tion of previously published clinical criteria.1
Exclusion criteria comprised PaO2 <8 kPa on FiO2
>0.7, positive end-expiratory pressure >15 cm
H2O, active bronchospasm, myocardial infarction
within the last 3 months, unstable arrhythmia,
mean arterial pressure <65 mm Hg on vasopressor
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therapy, bleeding diathesis (including platelet count <203109/l)
and initiation or modiﬁcation of antibiotics in the preceding
3 days.1 Patients who had had no change in prescribed antibiotics
for >3 days were included.1 13
Patients had ﬁbreoptic bronchoscopy and bronchoalveolar
lavage (BAL) performed by a single experienced operator using a
predeﬁned, standardised technique.14 15 Brieﬂy, where focal
inﬁltrates were present, the bronchoscope was wedged in
a subsegment corresponding to the area of radiological involve-
ment. In the case of diffuse radiographic change the broncho-
scope was wedged in a subsegment producing visible purulent
secretions or (in the absence of purulent secretions) in the
posterior segment of the right lower lobe. A 20 ml aliquot of
sterile saline was instilled and the aspirate (representing
a “bronchiolar” sample) discarded, then 200 ml of sterile saline
was instilled in aliquots and the aspirate (representing an alveolar
sample) retained. Whole blood was collected into 0.38% sodium
citrate (ﬁnal concentration).
Volunteer reference group
After recruitment of 40 patients the (anonymised) age and sex of
each patient was communicated to a local primary care practice,
where staff unconnected with the study randomly identiﬁed
matching individuals and sent out invitations to participate. The
ﬁrst twenty-one respondents were enrolled to form a reference
group. Exclusion criteria comprised hypoxia (SaO2 <92% on air),
bleeding diathesis, anticoagulant therapy, insulin-dependent
diabetes mellitus, arrhythmia, bronchospasm not responding to
nebulised b2 agonist or clinical evidence of respiratory tract infec-
tion. Eligible volunteers provided blood and had ﬁbreoptic bron-
choscopy and BAL performed by the same investigator as above.
Processing of BAL fluid (BALF) and whole blood
An aliquot of BALFwas sent to theNationalHealth Service (NHS)
Clinical Microbiology laboratory for culture, whilst simultaneous
cultureswere undertaken in our research laboratory. Sampleswere
processed using a standard operating procedure (SOP) in accor-
dance with the SOP for the processing of BAL issued by the UK
Health Protection Agency (HPA).16 Analyses were limited to
those routinely performed on BALF in our NHS laboratory (ie,
detailed analysis for viruses was not included), with the exception
that we additionally performed anaerobic cultures. BALF from
healthy volunteers was only cultured in the research laboratory.
Growth of >104 colony-forming units (cfu) per ml of lavage
ﬂuid conﬁrmed VAP.1 This deﬁnition is used by several infection
control and critical care organisations including the Hospitals in
Europe Link for Infection Control through Surveillance (HELICS)
programme.17 Patients whose BALF grew <104 cfu/ml formed
a “non-VAP” category. For further subgroup analysis “non-VAP”
was subdivided into “sub-VAP growth” and “sterile” groups. A
1 ml aliquot of BALF was collected for culture, and the remainder
centrifuged at 700 g for 10 min. Supernatant was immediately
frozen at 808C until further analysis. The cellular pellet was
resuspended in warmed Iscove’s modiﬁed Dulbecco’s medium
(IMDM; Invitrogen, Carlsbad, California, USA) and cytospins
produced. Cytospins were stained with Diff-Quik (Reagena,
Toivala, Finland) and differential cell counts established.
A 30 ml aliquot of citrated whole blood was separated into
cellular and plasma components by centrifugation.18 Serum was
prepared by adding 1 M calcium chloride to plasma.
Quantification of cytokines and inflammatory mediators
Concentrations of tumour necrosis factor-a (TNFa), interleukin
(IL)-1b, IL-6, IL-8, IL-10, granulocyte colony-stimulating factor
(G-CSF) and macrophage inﬂammatory protein-1a (MIP-1a) in
serum and BALF were estimated using cytometric bead array
(CBA) kits (BD Bioscience, Franklin Lakes, New Jersey, USA).
The concentrations of type 1 soluble triggering receptor
expressed on myeloid cells (sTREM-1) and monocyte chemo-
attractant peptide 1 (MCP-1) were measured by ELISA (R&D
Systems, Minneapolis, Minnesota, USA). Samples measured by
CBA and ELISA were diluted in an assay-dependent manner to
ensure they lay within the limits of the calibration curves.
The dilution required ranged from neat to 1:100 for the
highest values. Urea was measured by a colorimetric method
(QuantiChrom, Bioassay Systems, Hayward, California, USA)
and speciﬁcally used as a recognised means of correcting for
dilutional effects in BALF.19
Consent and ethics approval
Informed, witnessed assent was obtained from a relative or main
carer for all patients. Informed, written consent was obtained
from all volunteers. The study was approved by the relevant
Research Ethics Committees.
Statistical analysis
Statistical analysis was conducted using Prism (Graphpad
Software, San Diego, California, USA). Non-normally distrib-
uted data were analysed using the ManneWhitney U test for
two variables and the KruskaleWallis test for greater than two
variables, using the Dunn method for posthoc analysis. Normally
distributed data were analysed using the Student t test or anal-
ysis of variance (ANOVA) with the Bonferroni method for
posthoc analysis. Preliminary identiﬁcation of candidate
biomarkers was undertaken by noting those with signiﬁcant
differences between the VAP and “non-VAP” median values. The
diagnostic utility of these variables was assessed using area under
the receiver operator characteristic (ROC) curves. For those with
area under the curve values of $0.5, optimal cut-offs and likeli-
hood ratios were determined by the value with the maximum
Youden index20; a likelihood ratio is a likelihood that a person
with a positive (or negative) test has the disease in question. For
the two most promising candidates discriminating VAP from
“non-VAP”, multilevel likelihood ratios were calculated to illus-
trate diagnostic potential. Combinations of measures were
assessed for enhanced diagnostic potential by statistical model-
ling via logistic regression and classiﬁcation tree methods.
RESULTS
There were 74 eligible patients; 73 were enrolled, with one
excluded due to lack of a relative’s informed assent. Seventy-two
patients had recoverable BALF and so entered the analysis.
Seventeen (24%) grew organisms at >104 cfu/ml of BALF (“VAP
group”) (growing a median of 5.73104 cfu/ml, IQR
33104e63104 cfu/ml). Seven grew a Gram-positive organism,
six a Gram-negative organism, and four patients grew fungi,
including three yeasts (table 1). One patient growing a Gram-
positive organism also grew anaerobes. The remaining 55 patients
formed the “non-VAP” group, of whom 22 were categorised as
“sub-VAP” (ie, organisms cultured but at <104 cfu/ml of BALF,
growing amedian2.13102 cfu/ml (IQR 7.53102e43102 cfu/ml))
and 33 as “sterile”. Comparisons between cultures conducted in
the NHS laboratory and our laboratory revealed strong agree-
ment, with all patients identiﬁed as having VAP by the research
laboratory being similarly identiﬁed by the NHS laboratory.
There were no discordant cultures in this group. Amongst the
non-VAP group two patients grew bacteria (<102 cfu/ml) which
were not reported by the NHS laboratory, and one sample grew
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bacteria (<102 cfu/ml) in the NHS laboratory but not the
research laboratory. Twenty-one volunteers were recruited to
form the reference group. Twelve samples grew mixed oral
commensal ﬂora but always at <102 cfu/ml.
In the VAP group 18 species were grown from 17 patients (ie,
two organisms were grown from one patient); by deﬁnition
organisms were grown at >104 cfu/ml BALF. In the non-VAP
group 27 species were grown from 22 patients (ie, two organisms
were grown from ﬁve patients); by deﬁnition organisms were
grown at <104 cfu/ml BALF.
The three groups studied were closely matched with respect
to age (table 2). The VAP and non-VAP groups were similar with
regard to duration of mechanical ventilation, severity of illness
and co-morbidities (table 2). Although there was a greater like-
lihood of patients in the VAP group being male, having a surgical
reason for admission to ICU and having less acute lung injury
(ALI)/adult respiratory distress syndrome (ARDS), these differ-
ences did not reach statistical signiﬁcance (table 2).
All measured cytokines and inﬂammatory mediators in serum
showed similar concentrations in the VAP and non-VAP groups
(Supplementary table S1). No serum marker appeared to have
potential value for discriminating VAP from non-VAP, though
a trend in this direction was observed for sTREM-1. In general,
serum markers were higher in both patient groups than in
volunteers, with the exceptions of IL-1b and TNFa, which were
broadly similar in all three groups.
In contrast, the VAP group had signiﬁcantly higher concen-
trations of IL-1b, IL-8, G-CSF and MIP-1a in BALF than the non-
VAP group (table 3). Trends in the same direction were observed
for IL-6 and sTREM-1 (table 3).
On the basis of these ﬁndings, the capacity for IL-1b, IL-8, G-
CSF, MIP-1a, IL-6 and sTREM-1 to distinguish VAP among the
population with clinically suspected VAP was tested (ﬁgure 1).
For the ROC curves plotted in ﬁgure 1, area under the curve
correlates with the discriminatory value of the marker being
analysed. In this context IL-1b and IL-8 appeared to delineate
VAP most accurately. When optimal cut-off values were derived,
concentrations of BALF IL-1b <10 pg/ml appeared to be partic-
ularly powerful for the exclusion of VAP. Speciﬁcally, where BALF
IL-1b was <10 pg/ml, the negative likelihood ratio of 0.09 gives
a post-test probability of having VAP calculated at 2.8% (95% CI
0.1% to 15.9%). IL-1b proved less useful as a positive discrimi-
nator of VAP. In contrast, IL-8, whilst being less powerful for the
exclusion of VAP, had a broader diagnostic value. Thus, relative to
the identiﬁed cut-off value in ﬁgure 1 of 2000 pg/ml, a high BALF
IL-8 concentration increased the post-test probability of VAP
being present to 61.4% (95% CI 36.2% to 76.8%), derived from
the positive likelihood ratio of 5.03. These data are presented as
scatter plots in ﬁgure 2, illustrating that IL-1b has utility in
excluding VAP, but yields a number of false positives. In contrast,
IL-8 has a broader utility, but demonstrates a number of false-
positive and false-negative values. Multilevel likelihood ratios
demonstrated that increasing levels of BALF IL-8 lead to
increased conﬁdence for “ruling in” VAP, with the highest level
examined (4000 ng/ml) producing a post-test probability of 75%.
However, at this level, patient numbers are small and there is
a marked reduction in sensitivity (details are presented in
Supplementary table S2). A similar relationship was not
demonstrated for IL1-b (see table S2). G-CSF, MIP-1a, IL-6 and
sTREM-1 had markedly less discriminatory value than IL-1b or
IL-8. Statistical modelling using combinations of mediators (via
logistic regression and classiﬁcation tree methods) failed to add
discriminatory value to that achieved by either IL-1b or IL-8
alone. We did not ﬁnd any difference in cytokine levels between
VAPs caused by different classes of organism (Gram positive,
Gram negative or fungi). Interestingly all cases associated with
Candida albicans had cytokine levels above the optimum cut-off
point for diagnosis for IL-1b, IL-8, G-CSF and MIP-1a.
To examine the speciﬁcity of our ﬁndings, we analysed the
cytokine levels in the non-VAP group subdivided into those with
no growth (“sterile”) and those with growth below the 104 cfu/ml
cut off (“sub-VAP growth”). Cytokine concentrations did not
differ signiﬁcantly between the sub-VAP and sterile groups
(ﬁgure 3). No correlation was found between bacterial growth
Table 1 Organisms grown in patients with and without ventilator-
associated pneumonia (VAP)
Organisms VAP Non-VAP
Streptococcus pneumoniae 0 1
Methicillin-sensitive Staphylococcus
aureus
2 2
Methicillin-resistant S aureus 3 6
Coagulase-negative Staphylococcus spp. 2 1
Haemophilus influenzae 1 2
Escherichia coli 3 1
Citrobacter freundii 1 0
Citrobacter koseri 0 1
Enterobacter cloacae 1 2
Acinetobacter baumannii 0 1
Pseudomonas aeruginosa 0 2
Serratia marcescens 0 1
Klebsiella pneumoniae 0 4
Candida albicans 3 2
Aspergillus fumigatus 1 1
Anaerobes 1 0
Table 2 Demographic and clinical details of patients and age-/sex-matched volunteers
VAP (n[17) Non-VAP (n[55)
Matched
volunteers (n[21)
Mean age (range) 57 (31e83) 58 (25e87) 59 (24e84)
%Male 76% 55% 79%
Mean (95% CI) APACHE II score 23 (20e26) 21 (20e23) NA
Median (IQR) days of ventilation before enrolment 8 (6e9) 8 (5e10) NA
ICU mortality 35% 36% NA
% With surgical diagnosis on admission 65% 47% NA
% With $1 co-morbidity 59% 56% NA
% Receiving immunosuppressant drugs (including corticosteroids) 12% 11% NA
% Receiving antibiotics on day of diagnosis 29% 60% NA
% With acute lung injury/acute respiratory distress syndrome 17% 35% NA
% With systemic inflammatory response syndrome (SIRS) 88% 81% NA
APACHE II; Acute Physiology and Chronic Health Evaluation II; ICU, intensive care unit; NA, not applicable; VAP, ventilator-associated pneumonia.
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Figure 1 Receiver operating characteristic (ROC) curves and optimal sensitivity, specificity, positive predictive values (PPVs) and negative predictive
values (NPVs) for bronchoalveolar lavage fluid (BALF) cytokines (n¼72, 55 non-ventilator-associated pneumonia (VAP) and 17 VAP). Data are derived
from the patients with clinically suspected VAP. The broken line shows identity. G-CSF, granulocyte colony-stimulating factor; IL, interleukin; +LR,
positive likelihood ratio; LR, negative likelihood ratio; MIP 1-a, macrophage inflammatory protein-1a; sTREM-1; type 1 soluble triggering receptor
expressed on myeloid cells.
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and cytokine concentration when examining those patients with
growth below the 104 cfu/ml cut-off (r¼0.14, p¼0.31 for IL-8;
r¼0.06, p¼0.65 for IL-1b by Spearman rho).
DISCUSSION
These data have implications both for the diagnosis of VAP and
for understanding the biology of the disease. The practical
implications are that, in our hands, a patient with a BALF IL-1b
concentration<10 pg/ml has anw3% probability of having VAP.
In contrast, the probability of VAP being present increases as the
BALF IL-8 concentration increases; a level >2 ng/ml corre-
sponding to a 61% probability of VAP being present.
VAP remains common and associated with a high mortality.1 4
It is difﬁcult to diagnose accurately on clinical grounds alone,5 7 8
with a tendency to overdiagnosis leading to overprescription of
antibiotics.1 7 8 Diagnostic conﬁrmation remains largely reliant
on standard microbiological culture techniques which generally
take 24e48 h to yield results.15 In this regard, the capacity of IL-8
to increase the likelihood of a correct diagnosis ﬁvefold and/or the
capacity of low BALF IL-1b to reduce the likelihood of VAP 10-
fold is an important development. The assays used here can yield
a result within 4 h. These tests could therefore have a signiﬁcant
impact on clinical decision making.
These results also provide an interesting perspective on the
biology of VAP. For the majority of markers both patient groups
had higher levels than volunteers, implying a proinﬂammatory
state in critically ill patients as might be expected. However, it is
intriguing that acute inﬂammatory cytokines such as IL-1b and
MIP-1a were so similar when comparing the non-VAP group
with volunteers. Although non-signiﬁcant, there was a trend
towards more cases of ARDS/ALI in the non-VAP group. One
might have anticipated that these (ARDS/ALI) patients would
also demonstrate elevated cytokine levels21; however, we found
no difference between IL-8 and IL-1b levels within the non-VAP
Table 3 Inflammatory profile of bronchoalveolar lavage fluid (BALF)
VAP (n[17) Non-VAP (n[55)
Matched
volunteers (n[21)
p Value (Dunn
posthoc test
between VAP
and non-VAP)
Neutrophils (108/l)*** 2.8 (0.6e21) 3.2 (0.3e12) 0 (0e0.03) NS
Macrophages (108/l)* 2.3 (0.4e3.9) 1.6 (0.2e3.9) 2.9 (1.4e3.9) NS
IL-1b (pg/ml)*** 103 (27e755) 3 (0e48) 0 (0e1.6) <0.001
IL-8 (pg/ml)*** 6773 (2633e11762) 230 (68e1072) 69 (26e374) <0.001
TNFa (pg/ml) 1 (0e18) 0 (0e4) 0 (0e0) NS
IL-6 (pg/ml)*** 266 (105e503) 99 (10e465) 0 (0e6) NS
G-CSF (pg/ml)** 107 (38e383) 17 (5e89) 6 (0e25) <0.05
IL-10 (pg/ml)* 0 (0e9) 1 (0e16) 0 (0e0) NS
sTREM-1 (pg/ml) 13 (0e530) 0 (0e7) 0 (0e93) NS
MIP-1a (pg/ml)*** 51 (14e269) 3 (0e27) 2 (0e13) <0.01
MCP-1 (pg/ml)** 293 (94e554) 173 (49e1097) 21 (0e54) NS
Data are expressed as median and IQR. BALF values are corrected for dilution against concentrations of urea.19 Analysis by KruskalleWallis analysis of variance (ANOVA) allows detection of any
difference between the three groups (*<0.05. **<0.01, ***<0.001 shown in the left-hand column). Posthoc comparison between VAP and non-VAP groups was undertaken by Dunn posthoc
test, with the p value displayed in the right-hand column.
G-CSF, granulocyte colony-stimulating factor-1; IL, interleukin; MCP-1, monocyte chemoattractant peptide 1; MIP-1 a; macrophage inflammatory protein-1a; NS, non-significant; sTREM-1, type 1
soluble triggering receptor expressed on myeloid cells; TNFa, tumour necrosis factor a; VAP, ventilator-associated pneumonia.
Figure 2 Scatter plots of pulmonary
cytokine levels (n¼72, 55 non-
ventilator-associated pneumonia (VAP)
and 17 VAP). Each dot represents
a single observation. The solid lines
mark the median values; the hashed line
marks the optimal diagnostic cut-off. A
log scale is used due to the skewed
nature of cytokine levels. G-CSF,
granulocyte colony-stimulating factor;
IL, interleukin; MIP1-a, macrophage
inflammatory protein-1a;
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group when subdivided into those with ARDS/ALI and those
without. We believe this relates to the time point of sampling,
with our patients’ median length of stay prior to being recruited
being 8 days.
In contrast, the VAP group appeared to have a brisk inﬂam-
matory response conﬁned to the lung. We have no data relating
to the source of the relevant cytokines, but diffusion from serum
seems unlikely, suggesting a prominent role for alveolar epithe-
lium and/or lung macrophages. It is tempting to speculate that
sufﬁcient pathogens in the alveolar space drive a renewed and
compartmentalised inﬂammatory response. However, this study
was not designed to address this speciﬁc question and we cannot
exclude the possibility that VAP arises in those patients who ﬁrst
develop an upregulation of inﬂammation in the lung.
A number of potential biomarkers for VAP have been
proposed, including sTREM-1, procalcitonin, copeptin and
adrenomedullin.10e12 22 23 However, only sTREM-1 has been
found to have a stronger negative predictive value (or area under
the ROC curve) for VAP than the ﬁndings presented here,10 and
recent studies have found less impressive predictive capabilities
for sTREM-1 in BALF,24 25 in line with our observations. It is
interesting to consider why IL-1b and IL-8 have not been
identiﬁed as potential discriminatory markers in previous studies.
The compartmentalised nature of proinﬂammatory cytokines in
VAP has been noted previously,26 but the diagnostic capability
observed in our study was not seen. We believe this discrepancy
relates to the timing of investigation and reliance on rigorously
collected alveolar samples in our study.
We recommend caution when considering the general appli-
cability of our data. First, our results were generated using
bronchoscopy and lavage which may be contraindicated in some
patients, and remains relatively labour intensive and operator
dependent.27 An ideal diagnostic marker for VAP would involve
a highly discriminatory blood test. However. this remains elusive,
as reﬂected in Supplementary table S1. Debate continues as to
the optimal method for diagnosing VAP.28 The “gold standard”
for the diagnosis of pneumonia remains histology29; however,
this is neither desirable nor practicable in critically ill patients.
Therefore, uncertainty over the optimal method of diagnosis
affects all studies concerning VAP, especially those focusing on
diagnostic markers. A strength of our study lies in the fact that
we only recruited patients with predeﬁned clinically suspected
VAP using established criteria,1 17 and employed a rigorously
standardised, visually directed BAL procedure that was
conducted by a single experienced operator and relied on quan-
titative cultures to conﬁrm or refute VAP. To our knowledge these
speciﬁc, strict criteria have not been simultaneously applied in
previous studies seeking diagnostic markers for VAP. Our inci-
dence of conﬁrmed VAP (24%) is at the lower end of the reported
incidence, but is consistent with previous reports,30 and the 95%
CI (14% to 34%) for the true population incidence overlaps with
the estimate from several other reports.31 32 The precise timing of
sampling may also inﬂuence the diagnosis of VAP. Our data relate
speciﬁcally to the time of ﬁrst clinical suspicion of VAP, and are
based on the use of a particular assay system. Therefore, while
IL-1b and IL-8 are promising diagnostic markers, their diagnostic
usefulness (and the derived cut-off values) should be validated in
wider populations of ICU patients.
Secondly, there was a non-signiﬁcant trend towards more
“non-VAP” patients being on antibiotics at the time of bron-
choscopy. Antibiotics could have suppressed microbial growth to
some degree in these patients, although previous studies suggest
that after 3 days of unchanged antimicrobial treatment false-
negative cultures are unusual.1 13 Nevertheless, this does not
deﬂect the fact that marked rises in IL-1b and IL-8 only occurred
in patients with >104 cfu/ml (ﬁgure 3). This suggests that low
levels of bacterial growth may be tolerated in the alveolar space
and support the concept of clinical VAP emerging above
a bacterial threshold.1 15
Thirdly, the use of non-ventilated volunteers in this study can
be questioned. We would stress that this group was recruited as
a reference group only. The important question in clinical
practice is whether patients with a high clinical suspicion of
VAP have the condition or not; hence our critical comparison
was between the VAP and non-VAP groups.
A fourth caveat relates to the variable case mix and microbi-
ological epidemiology of ICUs.33 We included a wide variety of
surgical and medical cases, but no cardiothoracic cases were
involved. The range of bacteria isolated in this study broadly
reﬂects those described elsewhere, but is notable for the absence
of Pseudomonas aeruginosa. It may also be potentially relevant that
we did not culture for respiratory viruses. Finally, the inclusion of
fungi, especially Candida species, as causative organisms in VAP
remains controversial.1 34 35 However, we analysed our data
strictly in accordance with our predeﬁned diagnostic deﬁnitions
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Figure 3 Comparison of pulmonary cytokine levels between patients
with ventilator-associated pneumonia (VAP) (n¼17), patients with
growth of pathogens in bronchoalveolar lavage fluid (BALF) below the
diagnostic 104 cfu/ml cut-off (n¼22), and patients with no growth in
BALF (n¼33). (A) Interleukin-8 (IL-8) levels. Data are presented as the
median and IQRs, p<0.0001 by KruskaleWallis; NS (non-significant),
p>0.05, **p<0.01,***p<0.0001 by the Dunn posthoc test. (B) IL-1b
levels. Data are presented as the median and IQRs, p¼0.0006 by
KruskaleWallis; NS, p>0.05, **p<0.01,***p<0.0001 by the Dunn
posthoc test.
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which were based on the concentration of organisms (without
specifying the type). Interestingly we did not ﬁnd any difference
in cytokine levels between fungal and bacterial VAPs, with both
demonstrating a profound and characteristic pulmonary
inﬂammation. In our patients with VAP associated with fungal
growth, all four cytokines described in ﬁgure 1 were above the
optimal cut-off levels deﬁned by the ROC curves. While we
acknowledge that the small numbers involved mean that
statistical non-signiﬁcance could reﬂect a type two error, the data
suggest that fungal infection was associated with the same
pulmonary inﬂammation as the bacterial pathogens more typi-
cally associated with VAP. Furthermore, exclusion of C albicans
and/or coagulase-negative staphylococci (sometimes considered
“non-pathogenic” organisms) had no signiﬁcant effect on the
diagnostic usefulness of the cytokines as assessed by area under
the ROC curve (data not shown).
In conclusion, VAP is associated with increased pulmonary
IL-1b and IL-8. Further studies are warranted to validate IL-1b
and IL-8 as diagnostic markers able to inﬂuence important
clinical endpoints such antibiotic prescribing in ICUs.
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